Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Stromal cell-derived factor 1α (SDF-1α): A marker of disease burden in patients with atrial fibrillation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Atrial fibrillation and anticoagulation in patients with breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Role of Pannexin and adenosine triphosphate (ATP) following myocardial ischemia/reperfusion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Use of renal replacement therapy after out-of-hospital cardiac arrest in Denmark 2005-2013

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Organizational transformation in health care: an activity theoretical analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: Stromal cell-derived factor 1a (SDF-1α), is a chemokine and is able to home hematopoietic progenitor cells to injured areas of heart tissue for structural repair. Previous studies have found increased levels of SDF-1α in several cardiac diseases, but only few studies have investigated SDF-1α in patients with atrial fibrillation (AF). We aimed to test SDF-1α in a large cohort of patients with AF and its role as a prognostic marker Design: Between January 1st 2008 to December 1st 2012, 290 patients with ECG documented AF were enrolled from the in- and outpatient clinics at the Department of Cardiology, Copenhagen University Hospital, Hvidovre, Denmark. Plasma levels of SDF-1α were measured using ELISA technique. Clinical data were registered and patient follow-up was conducted.

RESULTS: Patients with permanent AF had significantly higher SDF-1α levels (2199.5 pg/ml) than patients with paroxysmal AF (1982.0 pg/ml) and persistent AF (1906.0 pg/ml), p<0.0005. Higher SDF-1α level was associated with longer time spent in the hospital per readmission, p<0.05.

CONCLUSION: In AF patients, a higher SDF-1α level was found in patients with a more progressive state of arrhythmia and was associated with longer hospitalizations. These findings suggest that SDF-1α could prove valuable in risk stratification and evaluating the disease burden in AF patients.

OriginalsprogEngelsk
TidsskriftScandinavian cardiovascular journal : SCJ
Vol/bind50
Udgave nummer1
Sider (fra-til)36-41
ISSN1401-7431
DOI
StatusUdgivet - 2016

ID: 45677544